Drug Trial Radar · NCT05322408
HCW9218 in Select Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Apr 1, 2022
Primary completion
Jan 2, 2025
Study completion Feb 28, 2025
Sponsor
- Lead sponsor
- Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single center, Phase I dose finding study of HCW9218 for the treatment of advanced/metastatic solid tumor cancer (except pancreatic and primary brain cancers). HCW9218 is a novel bi-functional fusion protein complex administered by subcutaneous (SC) injection. It is comprised of a soluble fusion of two human TGFβRII domains, human tissue factor, and human IL-15, and a second soluble fusion of two human TGFβRII domains and a sushi domain of human IL-15Rα. HCW9218 activates IL-15R signaling on effector immune cells and the dimeric TGFβRII functions as a "trap" for all three human TGF-β isoforms.
Conditions
- Solid Tumor
Interventions
HCW9218Drug
HCW9218 at the assigned dose level is administered as a subcutaneous injection once every 3 weeks for a minimum of 2 treatment cycles unless medically contraindicated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218Time frame: through study completion, an average of 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Masonic Cancer Center - University of Minnesota
Minneapolis, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.